Integra LifeSciences Supports Newest Edition of Guidelines for the Management of Severe TBI
Integra LifeSciences Holdings Corporation announced its support for the third edition of the Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury. The Guidelines are nationally recognized and referenced by many of the leading trauma centers in treatment of patients with traumatic brain injury. The Guidelines were developed by the Brain Trauma Foundation (BTF) in association with the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), and the AANS/CNS Joint Section on Neurotrauma and Critical Care, and incorporate the latest published research findings relevant to the diagnosis and treatment of severe traumatic brain injury. Guidelines include specific recommendations with regard to monitoring intracranial pressure (ICP) and brain tissue oxygen (BtO2) management. Intracranial pressure may be monitored by the Integra Camino(R) Advanced Monitor. Brain tissue oxygen may be monitored by the Integra Licox(R) Brain Tissue Oxygen Monitor. By educating health care providers in the use of these guidelines, the BTF estimates that thousands of lives could be saved in the U.S. and many would be spared life-long disabilities. With over 1000 trauma centers nationwide, more than 600,000 pre-hospital care providers, and a variety of physicians and nurses treating patients with severe TBI, it is an enormous challenge to get information to all those who care for brain injury patients in the U.S.
